DYN250117P60000
- 0.00
- 0.000.00%
Dyne Therapeutics Newsroom
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Analyst Ratings
Baird Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $46
Dyne Therapeutics Initiated With an Outperform at Baird
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Initiated at Outperform by RBC Capital
Dyne Therapeutics Analyst Ratings
RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Dyne Therapeutics Analyst Ratings
J.P. Morgan Downgrades Dyne Therapeutics(DYN.US) to Hold Rating, Cuts Target Price to $35
Dyne Therapeutics Downgraded to Neutral From Overweight at JPMorgan